{"id":"W3166432245","doi":"10.1200/jco.2021.39.15_suppl.4553","title":"Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Internal medicine; Sunitinib; Nivolumab; Cabozantinib; Renal cell carcinoma; Post-hoc analysis; Clinical trial; Progression-free survival; Gastroenterology; Surgery; Oncology; Cancer; Overall survival; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002469392,0.0006986331,0.0015362,0.0002477936,0.0002431508,0.0008149139,0.0005390358,0.0007079749,0.001973205],"category_scores_gemma":[0.001431194,0.0002315689,0.001575147,0.0002869586,0.0004610555,0.0006735152,0.0003131435,0.001696781,0.0003126614],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007632257,"about_ca_system_score_gemma":0.001057389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001015241,"about_ca_topic_score_gemma":0.003019429,"domain_scores_codex":[0.9993662,0.0003772143,0.00003573109,0.00009355052,0.0000456903,0.00008151175],"domain_scores_gemma":[0.999092,0.0002475867,0.0002552942,0.00005743345,0.00003860233,0.0003090831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.961093,0.004524205,0.003601958,0.0004295751,0.001285448,0.00003195113,0.00005189663,0.001293299,0.002730437,0.00006679687,0.0009719296,0.02391941],"study_design_scores_gemma":[0.5809399,0.3678443,0.03889592,0.0001026479,0.003070992,0.0002114403,0.00006950367,0.004260741,0.00206502,0.0005480658,0.001939573,0.00005185927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951179,0.002423571,0.0001697453,0.0001765719,0.00007109961,0.0005206231,0.0004993572,0.00003336172,0.0009877828],"genre_scores_gemma":[0.9972416,0.0005771384,0.0003426271,0.0002432991,0.0000802362,0.0003931406,0.0005693301,0.000007947795,0.0005446834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002469392,"threshold_uncertainty_score":0.01305956,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1593282888687688,"score_gpt":0.4703809437933762,"score_spread":0.3110526549246074,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}